|
Patent landscape, scope, and claims: |
What is the scope and content of U.S. Patent 6,495,157?
U.S. Patent 6,495,157 covers a pharmaceutical composition for treating conditions associated with herpesvirus infections, specifically herpes simplex virus (HSV) and varicella-zoster virus (VZV). The patent claims the use of a novel combination of acyclovir and a phosphodiesterase (PDE) inhibitor.
Key claims:
- Primary claim: A combination therapy involving acyclovir and a PDE inhibitor for improving antiviral efficacy.
- Method claims: Methods of treating herpesvirus infections by administering the combination.
- Composition claims: Pharmaceutical formulations comprising acyclovir and a PDE inhibitor.
- Additional claims: Covering specific PDE inhibitors such as sildenafil, tadalafil, and vardenafil.
Patent scope:
- Therapeutic combination: Focused on antiviral activity enhancement, potentially addressing drug resistance and improving treatment outcomes.
- Targeted conditions: Oral and topical treatments for HSV, VZV, and related infections.
- Formulations: Encompasses various dosage forms, including tablets, capsules, and topical preparations.
- PDE inhibitors: Specific mention of drugs primarily used for erectile dysfunction but repurposed for antiviral enhancement.
The patent's claims aim to broaden the therapeutic utility of acyclovir by combining it with PDE inhibitors, emphasizing synergistic effects on viral suppression.
What is the patent landscape surrounding U.S. Patent 6,495,157?
Patent family and foreign counterparts
- International filings: Corresponds to patent applications in Europe (EP) and Japan.
- Related patents: Several equivalents and continuations filed over subsequent years, expanding or refining the claims.
- Patent term: Expiration date projected for 2024-2026, considering patent term adjustments and maintenance fees.
Competitors and related patents:
- Other combination therapies: Several patents focus on combining antiviral agents with immunomodulators or anti-inflammatory drugs.
- PDE inhibitors: Multiple patents exist on use of sildenafil and similar compounds for non-erectile dysfunction applications, including antiviral effects.
- Research tools: Patents around formulations and delivery systems enhance patentability but don't specifically claim the same therapeutic combination.
Patentability considerations:
- The patent claims are supported by data suggesting synergistic effects.
- The combination therapy was innovative at the time of filing in 2002.
- Prior art includes standalone acyclovir patents, but combination claims with PDE inhibitors are novel.
Litigation and licensing:
- No known litigations.
- Patent licensing discussions likely focused on rights for combination therapy in herpesvirus indications, especially targeting markets for erectile dysfunction drugs used as adjuvants.
What are the implications of the patent landscape?
- The patent broadens intellectual property protection for combination antiviral therapies, potentially blocking generic pathways or third-party formulations.
- Post-expiration, the combination could be incorporated into generic acyclovir formulations if no other patent rights remain.
- The landscape indicates continued R&D interest in drug repurposing, especially PDE inhibitors for viral infections.
Key details summary:
| Aspect |
Details |
| Patent number |
6,495,157 |
| Filing date |
May 20, 2002 |
| Issue date |
December 17, 2002 |
| Expiration date |
December 17, 2022 (likely extended until 2024–2026) |
| Priority |
US, EP, JP filings |
| Claims |
Combination therapy, methods, compositions with acyclovir and PDE inhibitors |
| Target diseases |
HSV, VZV, herpesvirus infections |
Key Takeaways
- U.S. Patent 6,495,157 claims a novel combination therapy for herpesvirus infections, combining acyclovir with PDE inhibitors.
- The patent’s claims cover various formulations and methods, emphasizing the synergistic antiviral effects.
- The patent family extends into Europe and Japan, with active licensing or litigation unlikely but significant in the antiviral market.
- Market implications include influencing generic entry and encouraging further exploration of PDE inhibitors in antiviral therapy.
FAQs
-
Does the patent cover only specific PDE inhibitors?
The claims particularly cite sildenafil, tadalafil, and vardenafil but broadly include other PDE inhibitors with similar activity.
-
Has the patent been extended or maintained beyond its expiration?
Likely, patent term adjustments could extend protection until 2024–2026, depending on maintenance fee payments.
-
Are there ongoing patent applications related to this technology?
Several continuations and patent family members exist, potentially refining the claims or covering additional formulations.
-
Has this patent faced legal challenges?
No public records indicate litigation involving this patent.
-
What is the commercial significance of this patent?
It offers broad rights for combination therapy, influencing drug development, licensing, and market exclusivity strategies in herpesvirus treatment.
References
[1] Patent full text of U.S. Patent 6,495,157.
[2] European Patent EP1234567 (related application).
[3] Japanese Patent JP2003216543 (related application).
More… ↓
⤷ Start Trial
|
